阿斯利康公司（AstraZeneca Plc）的一款实验性胃癌药物在后期试验中使患者的生存时间延长了一倍，这提升了该药成为潜在重磅炸弹级药物的前景。
Plc’s experimental stomach cancer drug doubled the time patients survived in a late-stage trial, boosting prospects for a potential new blockbuster.
这种被称为sone-ve的抗体偶联药物，帮助那些在接受其他治疗后胃癌仍发生扩散的患者，比接受化疗及其他抗癌药物的患者多活了五个月。
The medicine, an antibody drug conjugate dubbed sone-ve, helped patients whose gastric cancer had spread despite other treatments live for five months longer than those receiving chemotherapy and other cancer drugs.
这家英国制药商的肿瘤血液学研发执行副总裁苏珊·加尔布雷思（Susan Galbraith）表示，研究结果加强了阿斯利康的信念，即抗体偶联药物——一类复杂的靶向疗法——可以在许多肿瘤治疗中取代化疗。
The results reinforce Astra’s belief that antibody drug conjugates — a class of complex targeted therapies — can replace chemotherapy in many tumors, said Susan Galbraith, the UK drugmaker’s executive vice president of oncology hematology research and development.
阿斯利康预计该疗法的潜在年销售额在30亿至50亿美元之间，其全称为sonesitatug vedotin。该药物靶向胃内壁中发现的一种蛋白质，这种蛋白质在某些胃癌中会有所表达。
Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and $5 billion. The medicine targets a protein found in the lining of the stomach that’s expressed in some gastric cancers.
在周日于欧洲肿瘤内科学会会议上公布的试验中，该药帮助那些在接受一种治疗后病情进展的患者延长了生命，但对于那些在接受过两线治疗后才使用该药的患者来说，获益更为显著。
In the trial presented Sunday at the European Society for Medical Oncology meeting, it helped patients whose cancer had progressed after one form of treatment live longer, but the greater benefit was for those getting it after two prior lines of medicine.
未参与该研究的法兰克福临床癌症研究所常务董事萨拉赫-埃丁·阿尔-巴特兰（Salah-Eddin Al-Batran）表示，对于这些患者而言，sone-ve很可能成为新的治疗策略。
For them, sone-ve will likely become the new treatment strategy, said Salah-Eddin Al-Batran, managing director of the Frankfurt Institute of Clinical Cancer Research, who wasn’t involved in the study.
不过，阿尔-巴特兰认为，在更广泛地采用该药物进行早期治疗之前，还需要更多的数据。
More data is needed, however, before widely adopting the drug for earlier treatment, according to Al-Batran.
该药物并未显示出有助于延缓疾病进展，加尔布雷思对此表示，这可能是因为胃癌的进展情况难以衡量。
The medicine didn’t show that it helped delay the disease’s progression, which Galbraith said could be because gastric cancer progression is difficult to measure.
在会议召开前，彭博行业研究（Bloomberg Intelligence）的分析师曾表示，如果sone-ve能显示出令人信服的生存获益，其年销售额可能高达22亿美元。
Before the conference, Bloomberg Intelligence analysts said sone-ve could bring in as much as $2.2 billion in annual sales if it showed a convincing survival gain.
研究显示，与使用sone-ve的患者相比，使用旧药物的患者因副作用而退出的比例更高，且与治疗相关的死亡人数大致相当。阿斯利康肿瘤业务部门执行副总裁戴夫·弗雷德里克森（Dave Fredrickson）表示，公司正在与卫生部门就这些数据进行沟通。
In the study, more patients dropped out due to side effects when they took the older medicines than sone-ve, and the number of deaths related to treatment was roughly similar. Astra is talking to health authorities about the data, said Dave Fredrickson, executive vice-president of the oncology business unit.
目前已有一款获批药物——安斯泰来制药（Astellas Pharma Inc.）的Vyloy——靶向同一种名为Claudin 18.2的蛋白质。但它仅适用于肿瘤中该蛋白质表达水平高得多的患者，这限制了符合条件的患者人数。
There is one approved drug – Astellas Pharma Inc.’s Vyloy – that targets the same protein, called Claudin 18.2. But it is only suitable for people whose tumors express much higher levels of the protein, limiting the number of eligible patients.
其他制药商也在追逐同一个靶点。根据在大会上公布的数据，在另一组胃癌患者群体中，武田制药（Takeda Pharmaceutical Co.）的arcotatug tavatecan帮助志愿者多活了三个多月。
Other drugmakers are going after the same target. In a different population of patients with stomach cancer, Takeda Pharmaceutical Co.’s arcotatug tavatecan helped volunteers live more than three months longer, according to data presented at the congress.
武田肿瘤治疗领域部门负责人Phuong Khanh Morrow表示，武田药物的独特之处在于减少了胃肠道副作用。她说，其作用机制“确实降低了任何恶心、呕吐和腹泻的风险”。
What sets Takeda’s drug apart is the reduced gastrointestinal side-effects, said Phuong Khanh Morrow, head of Takeda’s oncology therapeutic area unit. The mechanism of action “really reduces the risk of any nausea, vomiting, and diarrhea,” she said.
阿斯利康在会议上公布的其他数据包括重磅药物泰瑞沙（Tagrisso）与和黄医药（Hutchmed）及阿斯利康共同研发的药物Orpathys联合用药，针对一类非小细胞肺癌患者的后期试验结果。
Other data from Astra at the meeting included a late-stage trial of blockbuster Tagrisso combined with Orpathys, a medicine from Astra and Hutchmed, for patients with a type of non-small cell lung cancer.
与化疗相比，这种联合疗法将疾病进展延迟了两个多月，并将生存期延长了近五个月。由于癌细胞中某种蛋白质过度表达，这些患者的治疗难度特别大。
The combination delayed the disease’s progression by over two months and also extended life by almost five months compared with chemotherapy. Patients were particularly difficult to treat due to a type of protein being overly present in their cancer cells.
多伦多大学医学系教授娜塔莎·莱尔（Natasha Leighl）表示，这些数据很可能会“改变护理标准”。
The data will likely “change the standard of care,” said Natasha Leighl, professor in the Department of Medicine at the University of Toronto.
研究人员称，泰瑞沙和Orpathys均为可在居家服用的片剂，且这些药物具有可控的安全性。
Both Tagrisso and Orpathys are tablets that can be taken at home, with the medicines having a manageable safety profile, the researchers said.